Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
76 hedge funds and large institutions have $104M invested in Carisma Therapeutics in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 34 increasing their positions, 11 reducing their positions, and 5 closing their positions.
400% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 5
209% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 11
179% more capital invested
Capital invested by funds: $37.3M → $104M (+$67M)
36% more funds holding
Funds holding: 56 → 76 (+20)
0.12% more ownership
Funds ownership: 1.07% → 1.18% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
19% less call options, than puts
Call options by funds: $2.58M | Put options by funds: $3.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$7.09M |
| 2 |
Two Sigma Investments
New York
|
+$6.19M |
| 3 |
Two Sigma Advisers
New York
|
+$5.33M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.07M |
| 5 |
BlackRock
New York
|
+$2.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.1M |
| 2 |
EP
Eversept Partners
New York
|
-$2.11M |
| 3 |
TG
TRV GP
Boston,
Massachusetts
|
-$1.77M |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$944K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$411K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EP
76
Eversept Partners
New York
| – | -$2.11M | -77,991 | Closed |
|
|
MFS
77
Mirabella Financial Services
London,
United Kingdom
| – | -$119K | -4,418 | Closed |
|
|
BFM
78
Boothbay Fund Management
New York
| – | -$27K | -1,000 | Closed |
|
79
Man Group
London,
United Kingdom
| – | -$17K | -637 | Closed |
|
|
KC
80
Kinloch Capital
Glen Allen,
Virginia
| – | -$3K | -100 | Closed |
|
81
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$283 | +6 | New |
|
CARM Hedge Fund Activity: Q1 2021 in Review
76 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2021, worth a combined $104M — up 179% from $37.3M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CARM positions and 5 closed out — a net gain of 20 holders — while 34 added to existing stakes and 11 trimmed.
The largest buyer was Schonfeld Strategic Advisors, adding an estimated $7.09M. The largest seller was Morgan Stanley, cutting an estimated $4.1M.
- 76 institutional investors held Carisma Therapeutics (CARM) as of Q1 2021, up from 56 in Q4 2020.
- Funds reported $104M of Carisma Therapeutics stock for Q1 2021, up 179% quarter-over-quarter.
- 25 funds opened new Carisma Therapeutics positions in Q1 2021 and 5 closed out, a net change of +20 holders.
- The largest Carisma Therapeutics buyer in Q1 2021 was Schonfeld Strategic Advisors, an estimated $7.09M added.
- The largest Carisma Therapeutics seller in Q1 2021 was Morgan Stanley, an estimated $4.1M sold.
Based on aggregated 13F filings for Q1 2021.